Robert Burns
Recent Articles
Target Price Raised on Biotech Co. 09/25/2024
In an updated assessment of Zymeworks Inc.'s (ZYME:NYSE; ZYME:TSX) pipeline potential and upcoming catalysts, H.C. Wainwright & Co. analysts raised their target price on the company.
Leadership Cuts Won't Slow This Biotech 01/26/2024
While three executive officers have been cut from Kronos Bio Inc., it is still a Buy, according to an H.C. Wainwright & Co. report.
Boston Biotech Could Have Blockbuster Sales 01/03/2024
Tango Therapeutics may have "blockbuster potential," noted an H.C. Wainwright & Co. report.
Due to permission requirements, not all quotes are shown.
